marketing authorisation - Robuta Search

https://www.globenewswire.com/de/news-release/2026/04/15/3274537/28124/en/Legal-Requirements-for-a-Marketing-Authorisation-Holder-MAH-to-Offer-a-Medical-Information-Service-in-Europe-ONLINE-COURSE-June-22-2026.html Legal Requirements for a Marketing Authorisation Holder The program offers opportunities in enhancing skills for medical information specialists, focusing on legal requirements for MAHs, efficient medical... legal requirements marketing authorisation holder https://www.finanznachrichten.de/nachrichten-2026-03/68060429-eisai-and-nuvation-bio-announce-marketing-authorisation-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-011.htm Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the... - The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline- Additional... marketing authorisation eisai bio announce https://www.gov.uk/guidance/apply-to-change-a-veterinary-marketing-authorisation-or-homeopathic-remedy Apply to change a veterinary Marketing Authorisation or Homeopathic Remedy - GOV.UK Guidance for the pharmaceutical industry on how to apply to vary a veterinary Marketing Authorisation (MA) or Homeopathic Remedy. to change veterinary marketing https://www.esmo.org/oncology-news/ema-recommends-granting-a-conditional-marketing-authorisation-for-nadofaragene-firadenovec EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec | ESMO a conditional marketing authorisation nadofaragene firadenovec ema recommends https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-accepts-marketing-authorisation-application-for-momelotinib-for-the-treatment-of-myelofibrosis/ European Medicines Agency accepts marketing authorisation application for momelotinib for the... Application includes data from key phase III trials, including the pivotal MOMENTUM trial. european medicines agency marketing authorisation accepts application momelotinib https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-submits-european-marketing-authorisation-application-for-pazopanib-in-advanced-kidney-cancer/ GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced... GSK announced submission of MAA to EMEA for pazopanib, oral therapy for metastatic renal cell carcinoma (RCC). marketing authorisation glaxosmithkline submits european application https://www.biospace.com/averoa-submits-marketing-authorisation-application-to-the-european-medicines-agency-seeking-approval-of-ava1014-for-treating-complications-associated-with-chronic-kidney-disease AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking... Apr 24, 2024 - Averoa announces the submission of a marketing authorisation application to the European Medicines Agency for Ferric Citrate Coordination Complex, an oral... european medicines agency marketing authorisation to the submits application https://www.jnj.com/media-center/press-releases/janssen-submits-marketing-authorisation-application-to-the-european-medicines-agency-seeking-approval-of-lazertinib-in-combination-with-rybrevant-amivantamab-for-the-first-line-treatment-of-patients-with-egfr-mutated-non-small-cell-lung-cancer Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking... Nov 30, 2025 - The submission is supported by data from the Phase 3 MARIPOSA study, which featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO... european medicines agency marketing authorisation to the janssen submits https://www.jnj.com/media-center/press-releases/janssen-submits-marketing-authorisationapplication-to-the-european-medicines-agency-seeking-approval-of-erdafitinib-for-the-treatment-of-patients-with-locallyadvanced-or-metastatic-urothelial-cancer-with-susceptible-fgfr-alterations Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking... Nov 30, 2025 - Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor,1will become the... european medicines agency marketing authorisation to the janssen submits https://www.prnewswire.co.uk/news-releases/thrombogenics-announces-ema-acceptance-for-review-of-marketing-authorisation-application-for-ocriplasmin-144765755.html ThromboGenics Announces EMA Acceptance for Review of Marketing Authorisation Application for... /PRNewswire/ -- If Approved, Ocriplasmin Will be the First Pharmacological Treatment for Symptomatic Vitreomacular Adhesion (VMA) Including Macular Hole... for review marketing authorisation announces ema acceptance https://investingnews.com/eisai-and-nuvation-bio-announce-marketing-authorisation-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-validated-by-the-european-medicines-agency/ Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the... Mar 26, 2026 - The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timelineAdditional filings... marketing authorisation eisai bio announce https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-the-first-ever-dispersible-tablet-formulation-of-dolutegravir-tivicay-a-treatment-for-children-living-with-hiv-in-europe/ ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet... The EU Marketing Authorisation follows the US Food and Drug Administration (FDA) approval of Tivicay PD in 2020. viiv healthcare marketing authorisation https://www.esmo.org/oncology-news/ema-recommends-granting-a-marketing-authorisation-for-lurbinectedin EMA Recommends Granting a Marketing Authorisation for Lurbinectedin | ESMO marketing authorisation ema recommends granting lurbinectedin https://www.jnj.com/media-center/press-releases/janssen-submits-european-marketing-authorisation-application-for-canagliflozin-in-type-2-diabetes Janssen Submits European Marketing Authorisation Application for Canagliflozin in Type 2 Diabetes marketing authorisation